Cord Blood America, Inc., a provider of umbilical cord blood stem cell preservation for expectant parents and their children, recently announced that the company’s chief executive officer and co-founder, Matthew Schissler, was recently featured in an interview with analyst Francis Gaskins. In this interview, Mr. Schissler discusses the company’s expansion plans in China with AXM Pharma, Inc. (Pink Sheets: AXMP) to create the world’s largest stem cell storage facility.

Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood and immune disorders. The company’s expansion plans are based on the fact that a higher percentage of Chinese are interested in storing stem cells than in the U.S. and Europe. Although the barriers to entry into China are high and expensive, Cord Blood America’s partnership with AXM Pharma, Inc. will facilitate the company’s pathway to success. The entire interview is available at

Commenting on the company’s financial status, Mr. Schissler stated, “We now have a healthy balance sheet compared to where we were 12 months ago; the year 2010 will be dedicated to growing revenues.” Cord Blood America filed its annual financial report with the U.S. Securities & Exchange Commission last week.